Get started
Eli Lilly and CompanyEli Lilly and CompanyEli Lilly and Company

Eli Lilly and Company

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsSeasonalsOptionsBondsETFs

Chart


Full chart

Key facts today


Eli Lilly said tirzepatide cut all‑cause mortality by 57% vs insulin in a late‑stage CV outcomes trial in high‑risk diabetes/obesity patients; liver safety review found no issues.
Eli Lilly's Orforglipron (Foundayo) Phase 3 ACHIEVE-4: met primary endpoint, showing 16% lower MACE‑4 risk versus insulin glargine in overweight or high‑cardio‑risk Type 2 diabetes adults.
Eli Lilly (LLY) won U.S. approval April 1 for a weight‑loss drug and began direct‑to‑consumer sales immediately to speed early rollout — key for traders tracking uptake and revenue timing
Analyze the impactAnalyze the impact

Upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪855.09 B‬ USD
Dividend yield (indicated)
0.77%
Price to earnings Ratio (TTM)
40.06
Basic EPS (TTM)
22.62 USD
Net income (FY)
‪20.64 B‬ USD
Revenue (FY)
‪65.18 B‬ USD
Shares float
‪850.75 M‬
Beta (1Y)
0.42

Employees


Employees (FY)
‪50 K‬
Change (1Y)
‪+3 K‬ +6.38%
Revenue / Employee (1Y)
‪1.30 M‬ USD
Net income / Employee (1Y)
‪412.80 K‬ USD

About Eli Lilly and Company


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
David A. Ricks
Website
lilly.com
Headquarters
Indianapolis
Founded
1876
IPO date
Jul 9, 1970
Identifiers
3
ISIN US5324571083
CFI code
ESVUFR
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Check out other big names from the same industry as LLY.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Highest yielding bonds


5.762% YTM
Maturity date Sep 14, 2043
Coupon 1.63% (Fixed)
5.688% YTM
Maturity date Feb 12, 2065
Coupon 5.60% (Fixed)
5.684% YTM
Maturity date Feb 9, 2064
Coupon 5.10% (Fixed)
5.654% YTM
Maturity date Oct 15, 2065
Coupon 5.65% (Fixed)
5.634% YTM
Maturity date Aug 14, 2064
Coupon 5.20% (Fixed)
5.622% YTM
Maturity date Feb 27, 2063
Coupon 4.95% (Fixed)
5.589% YTM
Maturity date Mar 15, 2059
Coupon 4.15% (Fixed)
5.559% YTM
Maturity date Feb 9, 2054
Coupon 5.00% (Fixed)
5.545% YTM
Maturity date Feb 27, 2053
Coupon 4.88% (Fixed)
5.532% YTM
Maturity date Oct 15, 2055
Coupon 5.55% (Fixed)
5.529% YTM
Maturity date Mar 1, 2045
Coupon 3.70% (Fixed)

See all LLY bonds 

ETFs holding the stock


VTI
Vanguard Total Stock Market ETF
Weight 1.24%
Market value ‪24.81 B‬
VOO
Vanguard S&P 500 ETF
Weight 1.30%
Market value ‪18.56 B‬
IVV
iShares Core S&P 500 ETF
Weight 1.18%
Market value ‪9.17 B‬
SPY
SPDR S&P 500 ETF TRUST
Weight 1.18%
Market value ‪8.45 B‬
VUG
Vanguard Growth ETF
Weight 2.59%
Market value ‪8.25 B‬
XLV
State Street Health Care Select Sector SPDR ETF
Weight 13.57%
Market value ‪5.22 B‬
VIG
Vanguard Div Appreciation ETF
Weight 3.47%
Market value ‪4.08 B‬
IWF
iShares Russell 1000 Growth Fund
Weight 2.37%
Market value ‪2.91 B‬
VHT
Vanguard Health Care ETF
Weight 11.89%
Market value ‪2.22 B‬
0A3D
iShares Core S&P 500 UCITS ETF
Weight 1.19%
Market value ‪1.67 B‬
CSPX
iShares Core S&P 500 UCITS ETF
Weight 1.19%
Market value ‪1.67 B‬

Explore more ETFs 

Frequently asked questions


The current price of LLY is 922.48 USD — it has decreased by −0.11% in the past 24 hours. Watch Eli Lilly and Company stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Eli Lilly and Company stocks are traded under the ticker LLY.
LLY stock has fallen by −4.69% compared to the previous week, the month change is a −7.65% fall, over the last year Eli Lilly and Company has showed a 9.71% increase.
We've gathered analysts' opinions on Eli Lilly and Company future price: according to them, LLY price has a max estimate of 1,680.00 USD and a min estimate of 850.00 USD. Watch LLY chart and read a more detailed Eli Lilly and Company stock forecast: see what analysts think of Eli Lilly and Company and suggest that you do with its stocks.
LLY reached its all-time high on Jan 8, 2026 with the price of 1,133.95 USD, and its all-time low was 2.04 USD and was reached on Sep 21, 1977. View more price dynamics on LLY chart.
See other stocks reaching their highest and lowest prices.
LLY stock is 2.83% volatile and has beta coefficient of 0.42. Track Eli Lilly and Company stock price on the chart and check out the list of the most volatile stocks — is Eli Lilly and Company there?
Today Eli Lilly and Company has the market capitalization of ‪854.11 B‬, it has increased by 0.79% over the last week.
Yes, you can track Eli Lilly and Company financials in yearly and quarterly reports right on TradingView.
Eli Lilly and Company is going to release the next earnings report on Apr 30, 2026. Keep track of upcoming events with our Earnings Calendar.
LLY earnings for the last quarter are 7.54 USD per share, whereas the estimation was 6.91 USD resulting in a 9.10% surprise. The estimated earnings for the next quarter are 6.95 USD per share. See more details about Eli Lilly and Company earnings.
Eli Lilly and Company revenue for the last quarter amounts to ‪19.29 B‬ USD, despite the estimated figure of ‪17.94 B‬ USD. In the next quarter, revenue is expected to reach ‪17.60 B‬ USD.
LLY net income for the last quarter is ‪6.64 B‬ USD, while the quarter before that showed ‪5.58 B‬ USD of net income which accounts for 0.00% change. Track more Eli Lilly and Company financial stats to get the full picture.
Yes, LLY dividends are paid quarterly. The last dividend per share was 1.73 USD. As of today, Dividend Yield (TTM)% is 0.69%. Tracking Eli Lilly and Company dividends might help you take more informed decisions.
Eli Lilly and Company dividend yield was 0.56% in 2025, and payout ratio reached 26.14%. The year before the numbers were 0.67% and 44.39% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of Apr 17, 2026, the company has ‪50 K‬ employees. See our rating of the largest employees — is Eli Lilly and Company on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Eli Lilly and Company EBITDA is ‪31.69 B‬ USD, and current EBITDA margin is 48.62%. See more stats in Eli Lilly and Company financial statements.
Like other stocks, LLY shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Eli Lilly and Company stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Eli Lilly and Company technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Eli Lilly and Company stock shows the buy signal. See more of Eli Lilly and Company technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.